[1]施瑾,陈芷青*.妊娠期高血压疾病患者血浆生长分化因子-15 水平的测定及临床意义[J].中国计划生育和妇产科,2017,(5):48-51.
 SHI Jin,CHEN Zhi-qing*.Determination and clinical significance of plasma growth differentiation factor - 15 in hypertensive disorders complicating pregnancy[J].Chinese Journal of Family Planning & Gynecotokology,2017,(5):48-51.
点击复制

妊娠期高血压疾病患者血浆生长分化因子-15 水平的测定及临床意义
分享到:

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2017年5期
页码:
48-51
栏目:
论著与临床
出版日期:
2017-05-25

文章信息/Info

Title:
Determination and clinical significance of plasma growth differentiation factor - 15 in hypertensive disorders complicating pregnancy
作者:
施瑾陈芷青*
海门市人民医院妇科
Author(s):
SHI JinCHEN Zhi-qing*
Department of Gynaecology and Obstetrics , Haimen People 's Hospital, Haimen Jiangsu 226100, P.R. China
关键词:
妊娠期高血压疾病子痫生长分化因子-15
Keywords:
hypertensive disorders complicating pregnancy preeclampsia GDF-15
分类号:
R 714.252
摘要:
目的探讨孕妇血浆生长分化因子-15 (plasma growth differentiation factor-15,GDF-15)在妊娠期高血压疾病中的预测和诊断价值。方法选择2014年7月至2016年6月在海门市人民医院就诊及住院分娩的妊娠期高血压疾病孕妇137例,包括妊娠期高血压61例,轻度子痫前期28例,重度子痫前期27例,慢性高血压21例。另有同期在我院产前检查及住院分娩的正常单胎孕妇120例。所有正常孕妇及各组妊娠期高血压疾病孕妇分别按孕20周前、20~27周、28~35周、36周后再分组并
Abstract:
ObjectiveTo discuss the predictive and diagnostic value of plasma growth differentiation factor-15 (GDF-15) in women with hypertensive disorders complicating pregnancy.Methods137 women with hypertensive disorders complicating pregnancy including 61 gestational hypertension, 28 mild preeclampsia,27 severe preeclampsia and 21 chronic hypertension complicating pregnancy hospitlized in Haimen People's Hospital from July 2014 to June 2016 were collected. They were divided into four groups according to severity of disease. 120 normal pregnant women were collected over the same time as the control group. Testing the plasma GDF-15 in all women. Then, every group were further divided into 4 groups according to different gestational age as less than 20 weeks,20~27 weeks,28~35 weeks and more than 36 weeks. ResultsPlasma GDF-15 in preeclampsia group was significantly higher than other groups. Among them the severe group was higher than the mild group(P<005).GDF-15 in the gestational age more than 36 weeks group was significantly higher than that in gestational age less than 20 weeks,20~27weeks and 28~35weeks groups in severe preeclampsia pregnant(P<005). There were no differences in other groups throughout the pregnancy(P﹥005).ConclusionGDF-15 maybe a potential predictor of severity in hypertensive disorders complicating pregnancy.

参考文献/References:

[1]谢幸,苟文丽. 妇产科学 [M].第8版, 人民卫生出版社, 2013:64-65. [2]Bootcov MR,Bauskin AR,Valenzuela SM,et al.MIC-1,a novel macrophage inhibitory cytokine,is a divergentmember of the TGF-beta superfamily[J].Proc Natl AcadSci USA,1997, 94(21):11514-11519. [3]Lee ES, Kim SH, Kim HJ, et al. Growth Differentiation Factor-15 Predicts Chronic Liver Disease Severity [J]. Gut Liver, 2017, 11(2):276-282. [4]Anand IS, Kempf T, Rector TS, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the valsartan heart failure trial [J]. Circulation, 2010, 122(14): 1387-1395. [5]Wallentin L, Hijazi Z, Andersson U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial [J]. Circulation, 2014, 130 (21): 1847-1858. [6]Duley L. Pre-eclampsia and the hypertensive disorders of pregnancy [J]. Br Med Bull, 2003, 67(1):161–176. [7]Levine RJ, Lam C, Qian C, et al. Soluble edoglin and other circulating antiangiogenic factors in preeclampsia[J]. N Engl J Med, 2006, 355(10): 992 -1005. [8]Muller-Deile J, Schiffer M. Renal involvement in preeclampsia: similarities to VEGF ablation therapy[J].J Pregnancy, 2011(9237):176973. [9]Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia[J].Nat Med, 2006,12(6):624-649. [10]Bellamy L, Casas JP, Hingorani AD, et al. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis [J]. BMJ, 2007, 335(7627):974. [11]Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome [J]. Circulation, 2007, 115(8):962–971. [12]Kempf T, Bjorklund E, Olofsson S, et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction[J]. Eur Heart J, 2007, 28 (23):2858–2865. [13]Kempf T, von Haehling S, Peter T,et al. Prognostic utility of growth differentiationfactor-15 in patients with chronic heart failure [J]. J Am Coll Cardiol, 2007,50 (11):1054–1060. [14]Brown DA, Breit SN, Buring J,et al. Concentration inplasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study[J]. Lancet, 2002, 359(9324):2159–2163. [15]Lawton LN, Bonaldo MF, Jelenc PC, et al.Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta [J]. Gene, 1997, 203 (1):17–26. [16]Herse F, Dechend R, Harsem NK, et al.Dysregulation of the circulating and tissue-based renin-angiotensin system inpreeclampsia [J]. Hypertension, 2007, 49 (3):604–611. [17]Kempf T, Horn-Wichmann R, Brabant G, et al. Circulating concentration of growth –differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay [J]. Clin Chem, 2007, 53 (2):284-291.

相似文献/References:

[1]黄辉秀,谭毅.妊娠期高血压疾病预测和预防的研究现状[J].中国计划生育和妇产科,2009,(05):0.
 HUANG Hui-xiu,TAN Yi MCH Hospital of Fangcheng urban district,Fangchenggang city Guangxi automous region 80,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2009,(5):0.
[2]张珺,仲红丽.妊娠期高血压疾病监测系统预测及早期干预520例临床分析[J].中国计划生育和妇产科,2009,(06):0.
[3]肖兵,高岩,熊庆,等.妊娠期高血压疾病的流行病学研究进展[J].中国计划生育和妇产科,2010,(01):0.
[4]何怡,赵可文,唐莉,等.卡孕栓防治妊娠期高血压疾病产后出血的疗效观察[J].中国计划生育和妇产科,2010,(02):0.
 HE Yi,ZHAO Ke-wen,TANG LiMCH hospital of Dongguan city,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(5):0.
[5]庞春蓉,傅晓冬.肾上腺髓质素与妊娠期高血压疾病[J].中国计划生育和妇产科,2010,(02):0.
[6]陈倩,段成城,傅晓冬,等.血清T辅助细胞比率与妊娠期高血压疾病的关系和意义[J].中国计划生育和妇产科,2010,(03):0.
 CHEN Qian,DUAN Cheng-cheng,FU Xiao-dong..[J].Chinese Journal of Family Planning & Gynecotokology,2010,(5):0.
[7]陈茜松,刘丽俊,季淑英,等.妊娠期高血压疾病患者血清抵抗素水平的变化及其临床意义[J].中国计划生育和妇产科,2011,(03):0.
 CHEN Qian-song,LIU Li-jun,JI Shu-ying.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(5):0.
[8]侯卫萍,程兰,黄立,等.血清胱抑素C在妊娠期高血压疾病中的应用[J].中国计划生育和妇产科,2011,(06):0.
 HOU Wei-ping,CHENG Lan,HUANG Li.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(5):0.
[9]刘圣英,杨建恩.孕期补钙预防高危孕妇妊娠期高血压疾病的临床观察[J].中国计划生育和妇产科,2012,(03):0.
 LIU Sheng-ying,YANG Jian-en.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(5):0.
[10]金爽,尹春艳.IGF-Ⅰ、IGF-Ⅱ、IGFBP-1与妊娠期高血压疾病的相关性研究[J].中国计划生育和妇产科,2012,(05):0.
 JIN Shuang,YIN Chun-yan University of South China Teaching Hospital,the Second Peoples Hospital in Guangdong Province,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(5):0.
[11]史梦丹,周容.妊娠期高血压疾病眼部变化[J].中国计划生育和妇产科,2016,(04):0.
[12]黄梦威,梅劼*.妊娠期高血压疾病孕产妇转诊问题探讨[J].中国计划生育和妇产科,2018,(4):17.
[13]郑少娟,李亮*.凝血指标测定对妊娠期高血压疾病诊断与鉴别诊断的应用效果分析[J].中国计划生育和妇产科,2018,(10):43.
 ZHENG Shao-juan,LI Liang*.Analysis of application of coagulation index determination in diagnosis and differential diagnosis of hypertensive disorder complicating pregnancy[J].Chinese Journal of Family Planning & Gynecotokology,2018,(5):43.

更新日期/Last Update: 2017-05-25